OBIO
Orchestra BioMed Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
17.00%
of OBIO revenue · Ligand Pharmaceuticals Incorporated ("Ligand")
Orchestra BioMed has 5 disclosed suppliers and 5 disclosed customers in SEC filings.
Orchestra BioMed Holdings, Inc.
5.91
SentenceIn repayment of the Investment Amount, we will remit 17.0% of revenues related to the Products until an annual total of $17.0 million has been remitted to Ligand, thereafter we will remit (a) 4.0% of revenues related to the Primary Product in the field of hypertension treatment and (b) 4.0% of revenues related to the Secondary Product in the field of coronary artery treatment.
basisOBIO FY2025 revenue $33MLGND FY2025 revenue $268M
SentenceThe Moderato system, comprised of the implantable pulse generator ("IPG") and programmer, was manufactured under an original equipment manufacturer contract by a division of Integer Holdings Corporation ("Integer"), a leading supplier of cardiac rhythm management device components.
SentenceIn February 2023, we also contracted with MEDICO S.R.L. to develop a dual chamber pacemaker device that meets our specifications for running our cardiac neuromodulation therapies as well as standard pacing algorithms.
OBIO 10-Kaccession 0001104659-26-026754
SentenceThe disposable portion of the Pure-Vu EVS is manufactured by Sterling Industries in their Michigan, U.S. facility.
OBIO 10-Kaccession 0001104659-26-026754
SentenceIn addition, we concluded that Medtronic is a customer for a good or service that is a distinct unit of account, and therefore, the transact ions in the Medtronic Agreement, as amended pursuant to the Medtronic Agreement Amendment (the "Amended Medtronic Agreement"), should be accounted for under ASC 606.
SentenceThe Termination and ROFR Agreement, which supersedes and terminates the prior Virtue SAB distribution agreement between us and Terumo (the "Terumo Agreement"), grants Terumo a right of first refusal ("ROFR") to acquire the rights, or enter a distribution arrangement, with respect to Virtue SAB for the treatment of coronary artery disease, in exchange for an upfront payment of $10.0 million.
OBIO 10-Kaccession 0001104659-26-026754
SentenceThe Termination and ROFR Agreement, which supersedes and terminates the prior Virtue SAB distribution agreement between us and Terumo (the "Terumo Agreement"), grants Terumo a right of first refusal ("ROFR") to acquire the rights, or enter a distribution arrangement, with respect to Virtue SAB for the treatment of coronary artery disease, in exchange for an upfront payment of $10.0 million.
OBIO 10-Kaccession 0001104659-26-026754
SentenceThe Termination and ROFR Agreement, which supersedes and terminates the prior Virtue SAB distribution agreement between us and Terumo (the "Terumo Agreement"), grants Terumo a right of first refusal ("ROFR") to acquire the rights, or enter a distribution arrangement, with respect to Virtue SAB for the treatment of coronary artery disease, in exchange for an upfront payment of $10.0 million.
OBIO 10-Kaccession 0001104659-26-026754
Expected move
Inputsstraddle ±22.3%
spot 5.91exp Nov 20ATM strike 5ATM straddle 1.55IV 130%